Journal article
Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
DE Anderson, CW Tan, WN Chia, BE Young, M Linster, JGH Low, YJ Tan, MIC Chen, GJD Smith, YS Leo, DC Lye, LF Wang
Emerging Microbes and Infections | TAYLOR & FRANCIS LTD | Published : 2020
Open access
Abstract
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in gene..
View full abstractGrants
Awarded by National Foundation for Infectious Diseases
Funding Acknowledgements
This study was jointly supported by grants from the Singapore National Research Foundation (NRF-2016NRFNSFC002-013), and the National Medical Research Council of the Ministry of Health Singapore (CCGSFPOR20001, STPRG-FY19-001 and COVID19RF-003).